Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.
Saved in:
| Title: | Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia. |
|---|---|
| Authors: | Sun H; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA., Liu S; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Liu X; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Tsakmaklis N; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hatcher JM; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Guerrera ML; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Kofides A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Ramirez-Gamero A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Peachey AL; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA.; Department of Computer Science, Metropolitan College, Boston University, Boston, MA.; Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark., Chea V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Kim N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Lyu H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Lu W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Meid K; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Guijosa A; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Flynn CA; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Pizzarella D; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Patterson CJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hao M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Yuan W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Branagan AR; Department of Medicine, Harvard Medical School, Boston, MA.; Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Sarosiek SR; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Castillo JJ; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Hunter ZR; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Treon SP; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA. |
| Source: | Blood [Blood] 2026 May 14; Vol. 147 (20), pp. 2298-2314. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
